The European Food Safety Authority (EFSA) has issued a positive opinion on ingredient nicotinamide riboside (NR) for use in a food supplement at a daily serving of 300mg for the healthy adult population.
According to ChromaDex, the nutraceutical company that manufactures NR, this is a critical step in the EU regulatory approval process.
The company explains that cells can use NR, commercially known as Niagen, to create nicotinamide adenine dinucleotide (NAD), which is a molecule found in every living cell. ChromaDex notes that NAD plays an essential role in cellular energy product and supporting cellular repair, while decreased NAD levels are associated with many age-related declines in overall health.
CEO of ChromaDex Rob Fried said, “Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies. We are diligently working to complete the regulatory process to bring NR to the health-conscious people of the EU.”
The company plans to launch its flagship consumer NR product, Tru Niagen, in the EU once the regulatory process is completed.
